We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

1 hedge funds and large institutions have $65K invested in Loxo Oncology, Inc in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 231 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 2321 (-231)

100% less funds holding in top 10

Funds holding in top 10: 70 (-7)

100% less capital invested

Capital invested by funds: $4.15B → $65K (-$4.15B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 231

Holders
1
Holders Change
-231
Holders Change %
-99.57%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
231
Calls
Puts
Net Calls
Net Calls Change

LOXO Hedge Fund Activity: Q1 2019 in Review

1 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q1 2019, worth a combined $65K — down 100% from $4.15B a quarter earlier.

Sellers outnumbered buyers: 231 funds closed out of LOXO and 0 opened new positions — a net loss of 231 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $391M sold.

  • 1 institutional investor held Loxo Oncology, Inc (LOXO) as of Q1 2019, down from 232 in Q4 2018.
  • Funds reported $65K of Loxo Oncology, Inc stock for Q1 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Loxo Oncology, Inc positions in Q1 2019 and 231 closed out, a net change of -231 holders.
  • The largest Loxo Oncology, Inc seller in Q1 2019 was Vanguard Group, an estimated $391M sold.

Based on aggregated 13F filings for Q1 2019.